{"filing":{"accession_number":"0001104659-26-080308","cik":"0001828185","ticker":"BRNS","company_name":"Barinthus Biotherapeutics plc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"tm2619582d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926080308/tm2619582d1_8k.htm"},"events":[{"id":15814,"run_id":14107,"accession_number":"0001104659-26-080308","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Barinthus Biotherapeutics held its 2026 Annual General Meeting on July 2, 2026, with shareholders approving all seven ordinary resolutions, including re-election of directors Karen T. Dawes and Anne M. Phillips, re-appointment and ratification of PricewaterhouseCoopers LLP as auditors, authorization of auditor remuneration, receipt of annual accounts and dividend decision, and advisory approval of the directors' compensation report.","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13713,"accession_number":"0001104659-26-080308","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Barinthus Biotherapeutics' 2026 Annual General Meeting held on July 2, 2026. The filing reports final voting tallies on seven ordinary resolutions, including director re-elections (Karen T. Dawes and Anne M. Phillips), auditor re-appointment and ratification (PricewaterhouseCoopers LLP), auditor remuneration authorization, receipt of annual accounts and dividend decision, and advisory approval of the directors' compensation report. All matters were approved. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms governance outcomes and director/auditor continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:07:22.730949+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":15815,"run_id":14107,"accession_number":"0001104659-26-080308","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Barinthus Biotherapeutics received notice from Nasdaq on June 30, 2026, granting an additional 180-calendar-day compliance period (until December 28, 2026) to regain compliance with the $1.00 minimum bid price requirement after its ADSs were transferred from the Nasdaq Global Market to the Nasdaq Capital Market. If compliance is not regained by the deadline, Nasdaq will issue notice of delisting.","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13714,"accession_number":"0001104659-26-080308","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Barinthus Biotherapeutics received a Nasdaq notice on June 30, 2026, granting an additional 180-calendar-day compliance period (until December 28, 2026) to regain compliance with the $1.00 minimum bid price requirement. The company's ADSs were transferred from the Nasdaq Global Market to the Nasdaq Capital Market due to failure to meet the Bid Price Requirement. The disclosure explicitly states that if compliance is not regained, \"Nasdaq will provide notice that the ADSs will be subject to delisting,\" making this a clear delisting risk disclosure under Item 3.01 principles, disclosed here under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:07:22.730949+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13713,"accession_number":"0001104659-26-080308","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Barinthus Biotherapeutics' 2026 Annual General Meeting held on July 2, 2026. The filing reports final voting tallies on seven ordinary resolutions, including director re-elections (Karen T. Dawes and Anne M. Phillips), auditor re-appointment and ratification (PricewaterhouseCoopers LLP), auditor remuneration authorization, receipt of annual accounts and dividend decision, and advisory approval of the directors' compensation report. All matters were approved. This is a quintessential Item 5.07 disclosure and is material to investors as it confirms governance outcomes and director/auditor continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:07:22.730949+00:00","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-07-02"},{"id":13714,"accession_number":"0001104659-26-080308","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Barinthus Biotherapeutics received a Nasdaq notice on June 30, 2026, granting an additional 180-calendar-day compliance period (until December 28, 2026) to regain compliance with the $1.00 minimum bid price requirement. The company's ADSs were transferred from the Nasdaq Global Market to the Nasdaq Capital Market due to failure to meet the Bid Price Requirement. The disclosure explicitly states that if compliance is not regained, \"Nasdaq will provide notice that the ADSs will be subject to delisting,\" making this a clear delisting risk disclosure under Item 3.01 principles, disclosed here under Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:07:22.730949+00:00","company_name":"Barinthus Biotherapeutics plc.","ticker":"BRNS","filing_date":"2026-07-02"}]}